Significant ETF Withdrawals for UVIX and SYNB
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 17 2025
0mins
Source: NASDAQ.COM
ETF Outflow Details: The Putnam BioRevolution ETF experienced the largest outflow, losing 50,000 units, which is a 40.0% decline in outstanding units compared to the previous week.
Market Performance: In morning trading, Thermo Fisher Scientific saw a slight decrease of about 0.3%, while Abbvie experienced a modest increase of approximately 0.9%.
Video Content: A video segment discusses significant ETF outflows, specifically mentioning UVIX and SYNB.
Author's Perspective: The views expressed in the article are those of the author and do not necessarily represent the opinions of Nasdaq, Inc.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 224.770
Low
223.00
Averages
252.00
High
289.00
Current: 224.770
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified, research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. The aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Duodopa is a levodopa-carbidopa intestinal gel for the treatment of Parkinson's disease. Eye care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Top High-Yield Dividend Stocks: AbbVie, Chevron, Enterprise
- AbbVie's Strong Growth: AbbVie markets 12 blockbuster drugs, with 7 generating over $2 billion in annual sales, and boasts a 54-year streak of dividend increases, currently yielding 3%, positioning it strongly in the pharmaceutical sector.
- Chevron's Stable Returns: Chevron has increased its dividend for 39 consecutive years, with a current yield of 3.8%, and has repurchased shares in 18 of the last 22 years, demonstrating a strong commitment to shareholder returns, with expected annual EPS growth of over 10%.
- High Yield from Enterprise Products: Enterprise Products Partners offers a distribution yield of 5.8% and has increased distributions for 27 consecutive years, supported by a strong balance sheet and high credit rating, indicating continued growth potential.
- Market Environment Impact: With rising inflation and a strong job market, increased market volatility may occur, yet high-yield stocks like AbbVie, Chevron, and Enterprise Products are likely to attract income-seeking investors, potentially driving their stock prices higher.
See More
Teva Pharmaceutical's Recovery: Challenges and Opportunities in Biosimilars
- Stock Price Recovery: Teva Pharmaceutical's stock has surged by 97% over the past year, indicating a significant recovery from previous challenges including debt and litigation, although the current price may not present an ideal buying opportunity.
- Biosimilars Market: Teva has launched two biosimilars in partnership with Alvotech, namely Simlandi in May 2024 and Selarsdi in February 2025, with expectations for its biosimilars business to double to around $800 million by 2027, despite facing fierce competition and narrow profit margins.
- Branded Drug Performance: The company's resurgence is primarily driven by its branded drugs, particularly Austedo, which achieved approximately $2.3 billion in sales in 2025, highlighting strong demand in treating movement disorders, although overall revenue is projected to be flat or decline in 2026.
- Investor Caution: Despite the evident recovery, Teva's current P/E ratio of about 25 suggests that its valuation is no longer attractive, prompting investors to carefully assess future growth potential, especially as better investment opportunities may exist in other areas of the pharmaceutical industry.
See More
AbbVie Showcases New Data in Blood Cancer Portfolio
- Dividend Appeal: AbbVie's dividend yield exceeds 3%, significantly higher than the sub-2% yields of blue-chip healthcare stocks like Eli Lilly, Johnson & Johnson, and Amgen, indicating strong cash flow support that helps attract investors and bolster market confidence.
- EHA Conference Presentation: At the European Hematology Association Congress, AbbVie showcased 21 clinical data presentations on various blood cancers, enhancing its reputation in the treatment space and potentially facilitating future regulatory approvals and partnerships, thereby driving revenue growth.
- Diversified Revenue Streams: In 2025, AbbVie's oncology portfolio generated approximately $6.7 billion in revenue, helping to reduce reliance on Humira and enhancing overall business resilience, ensuring sustained cash flow to support dividend payments.
- Ongoing R&D Investment: AbbVie is actively investing in expanding existing therapies and developing next-generation treatments, aiming to create new revenue sources through successful clinical trials, ensuring that oncology continues to be a growth driver and further solidifying its dividend-paying capacity.
See More
AbbVie Expands Blood Cancer Treatment Market with New Data
- Market Expansion Potential: AbbVie showcased 21 research data points on blood cancers at the European Hematology Association Congress, covering various types including chronic lymphocytic leukemia, which could open new indications for existing drugs and drive future revenue growth.
- Revenue Diversification: In 2025, AbbVie's oncology portfolio generated approximately $6.7 billion in revenue, highlighting its significance as a revenue source despite the focus on immunology, thereby supporting R&D and dividend payments.
- Risk Management Strategy: In response to the challenges posed by Humira's patent expiration, AbbVie has aggressively built new growth platforms across immunology, oncology, and neuroscience, reducing dependence on any single product and enhancing cash flow resilience.
- Clinical Trial Outlook: AbbVie continues to invest in expanding existing therapies into new indications and advancing next-generation blood cancer treatments, with successful clinical trials creating potential for new approvals, larger patient populations, and longer revenue runways, ensuring long-term cash flow to support dividend growth.
See More
AbbVie Presents Landmark Nine-Year CLL14 Trial Results
- Long-Term Efficacy: AbbVie presented nine-year results from the CLL14 trial at the 2026 European Hematology Association Congress, demonstrating the long-term efficacy and safety of venetoclax combined with obinutuzumab for previously untreated chronic lymphocytic leukemia (CLL).
- Superior Treatment Outcomes: The trial showed that patients receiving venetoclax plus obinutuzumab achieved a median progression-free survival of 6.4 years, significantly better than the 3.2 years seen with obinutuzumab plus chlorambucil (HR 0.50, p<0.001), indicating the new regimen's potential to extend patient survival.
- Quality of Life Improvement: This combination therapy provided meaningful time without CLL-specific treatment, allowing patients to enjoy extended quality of life benefits after just one year of fixed-duration therapy, further solidifying venetoclax as a first-line treatment option.
- Consistent Safety Profile: The safety profile remained consistent with prior reports, with the most common Grade 3 adverse events being neutropenia, thrombocytopenia, anemia, and pneumonia, indicating the regimen's acceptability for long-term use.
See More
AbbVie Unveils New Phase 3 Data on Venetoclax for CLL at EHA 2026
- Clinical Trial Results: AbbVie's presentation at the EHA 2026 Congress revealed that the CLL14 trial's nine-year data demonstrated significant safety and efficacy for the venetoclax and obinutuzumab combination, with a median progression-free survival (PFS) of 6.4 years compared to 3.2 years in the control group, indicating long-term effectiveness in chronic lymphocytic leukemia (CLL) patients.
- Extended Treatment Intervals: The study also highlighted a median time to next treatment (TTNT) of 7.6 years for patients receiving venetoclax plus obinutuzumab, allowing for longer periods without treatment, which not only enhances patient quality of life but also strengthens AbbVie's leadership position in blood cancer therapies.
- Safety Analysis: Among patients treated with the venetoclax combination, the most frequently reported Grade 3 adverse events included neutropenia and thrombocytopenia; however, the overall safety profile remains acceptable, laying a solid foundation for the clinical application of this therapy.
- Market Outlook: With venetoclax approved in over 80 countries, AbbVie's research findings not only bolster its competitive edge in the global market but also provide renewed impetus for further research and development in CLL and other hematological malignancies.
See More
Top High-Yield Dividend Stocks: AbbVie, Chevron, Enterprise
- AbbVie's Strong Growth: AbbVie markets 12 blockbuster drugs, with 7 generating over $2 billion in annual sales, and boasts a 54-year streak of dividend increases, currently yielding 3%, positioning it strongly in the pharmaceutical sector.
- Chevron's Stable Returns: Chevron has increased its dividend for 39 consecutive years, with a current yield of 3.8%, and has repurchased shares in 18 of the last 22 years, demonstrating a strong commitment to shareholder returns, with expected annual EPS growth of over 10%.
- High Yield from Enterprise Products: Enterprise Products Partners offers a distribution yield of 5.8% and has increased distributions for 27 consecutive years, supported by a strong balance sheet and high credit rating, indicating continued growth potential.
- Market Environment Impact: With rising inflation and a strong job market, increased market volatility may occur, yet high-yield stocks like AbbVie, Chevron, and Enterprise Products are likely to attract income-seeking investors, potentially driving their stock prices higher.
See More
Teva Pharmaceutical's Recovery: Challenges and Opportunities in Biosimilars
- Stock Price Recovery: Teva Pharmaceutical's stock has surged by 97% over the past year, indicating a significant recovery from previous challenges including debt and litigation, although the current price may not present an ideal buying opportunity.
- Biosimilars Market: Teva has launched two biosimilars in partnership with Alvotech, namely Simlandi in May 2024 and Selarsdi in February 2025, with expectations for its biosimilars business to double to around $800 million by 2027, despite facing fierce competition and narrow profit margins.
- Branded Drug Performance: The company's resurgence is primarily driven by its branded drugs, particularly Austedo, which achieved approximately $2.3 billion in sales in 2025, highlighting strong demand in treating movement disorders, although overall revenue is projected to be flat or decline in 2026.
- Investor Caution: Despite the evident recovery, Teva's current P/E ratio of about 25 suggests that its valuation is no longer attractive, prompting investors to carefully assess future growth potential, especially as better investment opportunities may exist in other areas of the pharmaceutical industry.
See More
AbbVie Showcases New Data in Blood Cancer Portfolio
- Dividend Appeal: AbbVie's dividend yield exceeds 3%, significantly higher than the sub-2% yields of blue-chip healthcare stocks like Eli Lilly, Johnson & Johnson, and Amgen, indicating strong cash flow support that helps attract investors and bolster market confidence.
- EHA Conference Presentation: At the European Hematology Association Congress, AbbVie showcased 21 clinical data presentations on various blood cancers, enhancing its reputation in the treatment space and potentially facilitating future regulatory approvals and partnerships, thereby driving revenue growth.
- Diversified Revenue Streams: In 2025, AbbVie's oncology portfolio generated approximately $6.7 billion in revenue, helping to reduce reliance on Humira and enhancing overall business resilience, ensuring sustained cash flow to support dividend payments.
- Ongoing R&D Investment: AbbVie is actively investing in expanding existing therapies and developing next-generation treatments, aiming to create new revenue sources through successful clinical trials, ensuring that oncology continues to be a growth driver and further solidifying its dividend-paying capacity.
See More
AbbVie Expands Blood Cancer Treatment Market with New Data
- Market Expansion Potential: AbbVie showcased 21 research data points on blood cancers at the European Hematology Association Congress, covering various types including chronic lymphocytic leukemia, which could open new indications for existing drugs and drive future revenue growth.
- Revenue Diversification: In 2025, AbbVie's oncology portfolio generated approximately $6.7 billion in revenue, highlighting its significance as a revenue source despite the focus on immunology, thereby supporting R&D and dividend payments.
- Risk Management Strategy: In response to the challenges posed by Humira's patent expiration, AbbVie has aggressively built new growth platforms across immunology, oncology, and neuroscience, reducing dependence on any single product and enhancing cash flow resilience.
- Clinical Trial Outlook: AbbVie continues to invest in expanding existing therapies into new indications and advancing next-generation blood cancer treatments, with successful clinical trials creating potential for new approvals, larger patient populations, and longer revenue runways, ensuring long-term cash flow to support dividend growth.
See More
AbbVie Presents Landmark Nine-Year CLL14 Trial Results
- Long-Term Efficacy: AbbVie presented nine-year results from the CLL14 trial at the 2026 European Hematology Association Congress, demonstrating the long-term efficacy and safety of venetoclax combined with obinutuzumab for previously untreated chronic lymphocytic leukemia (CLL).
- Superior Treatment Outcomes: The trial showed that patients receiving venetoclax plus obinutuzumab achieved a median progression-free survival of 6.4 years, significantly better than the 3.2 years seen with obinutuzumab plus chlorambucil (HR 0.50, p<0.001), indicating the new regimen's potential to extend patient survival.
- Quality of Life Improvement: This combination therapy provided meaningful time without CLL-specific treatment, allowing patients to enjoy extended quality of life benefits after just one year of fixed-duration therapy, further solidifying venetoclax as a first-line treatment option.
- Consistent Safety Profile: The safety profile remained consistent with prior reports, with the most common Grade 3 adverse events being neutropenia, thrombocytopenia, anemia, and pneumonia, indicating the regimen's acceptability for long-term use.
See More
AbbVie Unveils New Phase 3 Data on Venetoclax for CLL at EHA 2026
- Clinical Trial Results: AbbVie's presentation at the EHA 2026 Congress revealed that the CLL14 trial's nine-year data demonstrated significant safety and efficacy for the venetoclax and obinutuzumab combination, with a median progression-free survival (PFS) of 6.4 years compared to 3.2 years in the control group, indicating long-term effectiveness in chronic lymphocytic leukemia (CLL) patients.
- Extended Treatment Intervals: The study also highlighted a median time to next treatment (TTNT) of 7.6 years for patients receiving venetoclax plus obinutuzumab, allowing for longer periods without treatment, which not only enhances patient quality of life but also strengthens AbbVie's leadership position in blood cancer therapies.
- Safety Analysis: Among patients treated with the venetoclax combination, the most frequently reported Grade 3 adverse events included neutropenia and thrombocytopenia; however, the overall safety profile remains acceptable, laying a solid foundation for the clinical application of this therapy.
- Market Outlook: With venetoclax approved in over 80 countries, AbbVie's research findings not only bolster its competitive edge in the global market but also provide renewed impetus for further research and development in CLL and other hematological malignancies.
See More
